news > industry > article

99mTc-maraciclatide SPECT for prostate cancer bone metastases

Kevin Yang Kevin Yang ⎜ Mar 12, 2018 ⎜ Industry

Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy.

Conclusion: 99mTc-maraciclatide accumulates in PCa bone metastases in keeping with increased αvβ3 integrin expression. Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar and SPECT T:M ratios after 12 weeks of treatment differed between patients with and without PD and 99mTc-maraciclatide imaging may be a potential method for assessing early response.

Cook, G.J.R., Azad, G.K., Taylor, B.P. et al. Eur J Nucl Med Mol Imaging (2018).

For full article, please access: